TRMT2B is responsible for both tRNA and rRNA m⁵U-methylation in human mitochondria

Christopher A. Powell¹ and Michal Minczuk^{1*}

¹ Medical Research Council Mitochondrial Biology Unit, University of Cambridge, Hills Road, Cambridge CB2 0XY, UK

*Corresponding author:

Michal Minczuk, e-mail: michal.minczuk@mrc-mbu.cam.ac.uk Medical Research Council Mitochondrial Biology Unit, University of Cambridge, The Keith Peters Building, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0XY, UK

Abstract

RNA species play host to a plethora of post-transcriptional modifications which together make up the epitranscriptome. 5-methyluridine (m⁵U) is one of the most common modifications made to cellular RNA, where it is found almost ubiquitously in bacterial and eukaryotic cytosolic tRNAs at position 54. Here, we demonstrate that m⁵U54 in human mitochondrial tRNAs is catalysed by the nuclear-encoded enzyme TRMT2B, and that its repertoire of substrates is expanded to ribosomal RNAs, catalysing m⁵U429 in 12S rRNA. We show that TRMT2B is not essential for viability in human cells and that knocking-out the gene shows no obvious phenotype with regards to RNA stability, mitochondrial translation, or cellular growth.

KEYWORDS: mitochondria, tRNA, rRNA, post-transcriptional modifications, 5-methyluridine

Introduction

The accurate expression of the human mitochondrial genome (mtDNA) is essential for the faithful synthesis of 13 components of the oxidative phosphorylation machinery. In order to achieve this, the 22 tRNAs and 2 rRNAs encoded in the mtDNA undergo significant post-transcriptional modification performed by nuclear-encoded proteins imported into mitochondria¹.Recent data indicate that defects in the nucleotide modification of mitochondrial (mt-) RNA can frequently lead to human disorders of mitochondrial respiration^{2–5}

5-methyluridine (m⁵U), is found with high occurrence in bacterial and eukaryotic tRNAs at position 54 in the T-loop, including, although significantly less common, human mitochondrial tRNAs. Although first identified in tRNAs, the T-loop motif has now been identified in a wide array of different non-coding RNAs, including the tmRNA of bacteria⁶, RNase P RNA⁷, self-splicing introns⁸, and riboswitches⁹, implying that this frequently occurring motif is an important structural building block. T-loops have additionally been implicated in stabilising the tertiary fold of rRNA, this has been suggested to occur either via base pairing/base pairing tertiary interactions or by stabilizing stems by forming a non-interacting caps¹⁰. The m⁵U modification is also found in a number of rRNA species, including that of the mitochondrial small rRNA in hamster^{11,12}however as before, their exact contribution to the surrounding tertiary structure is uncertain.

The vast majority of methyltransferases that catalyse m⁵U formation utilise SAM (Sadenosyl-methionine) as a methyl donor, however a small number including TrmFO subtilis¹³ and RImFO from М. capricolum¹⁴, from methylenetetrahydrofolate (M-THF) as a methyl source. The most well studied m⁵Umethyltransferases, all of which fall into the former, SAM-dependent, group, are the three expressed by E. coli: RImC, RImD, and TrmA. Both RImC and RImD methylate the 23S rRNA of the large subunit, with the former producing m⁵U747 and the latter producing m⁵U1939¹⁵. The aforementioned m⁵U54 tRNA modification is catalysed by TrmA, which also methylates the T-loop in *E.coli* tmRNA¹⁶. TrmA has additionally been found to methylate bacterial 16S rRNA in vitro, however this modification is not found

*in vivo*¹⁷. The proposed catalytic mechanism utilised by m⁵U-methyltransferases has been supported by the crystal structure of the TrmA-tRNA complex in which the sulphhydryl-group of a conserved cysteine acts as a nucleophile to attack C6, leading to the formation of a covalent bond between the two. The resulting negative charge on O4 prompts a second nucleophilic attack by the C5 carbon on the methyl group of SAM, forming m⁵U. A second highly conserved residue, a glutamate, acts as a base to abstract a proton from C5 leading to the elimination of the covalent adduct and its release from the regenerated active site 18. The identification and characterisation of TrmA has not brought the field significantly closer to understanding the exact role of m⁵U54, as mutations in *E.coli* TrmA that lead to the complete loss of methyltransferase activity revealed no perceptible difference in growth rate, codon recognition, ribosome interaction, or translation rate in vivo¹⁹. A growth defect in the TrmA mutant cells was only observed following growth in a mixed culture in which the two strains directly competed. Interestingly, the TrmA protein itself, but not its known enzymatic activity, is found to be essential for viability. An insertion within the trmA gene corresponding to the N-terminus of the protein is lethal, therefore it is proposed that TrmA has a secondary essential function that is separate from its methyltransferase activity²⁰.

The loss of m⁵U54 from both cytoplasmic and mitochondrial tRNAs was first observed in eukaryotic cells following the deletion of the trm2 gene in S.cerevisiae²¹. As was the case for bacterial TrmA, the loss of Trm2 showed no physiological defect compared to wild-type cells, however even in cocultures of mixed populations, the wild-type cells demonstrated no selective advantage over the mutant strain after 35 generations. The requirement for trm2 is further contrasted from that of trmA by the nonessential nature of not only m⁵U54 but of the protein itself, as a complete deletion of *trm2* also shows no physiological defect²². The large majority of homology between TrmA and Trm2 lies towards the C-terminus containing the known methyltransferase domain, with little homology towards the N-terminus. This, therefore, supports the notion that the unidentified essential function of TrmA is situated towards the N-terminus, and that this function is either not performed by Trm2 or there is a greater degree of functional redundancy in eukaryotic cells. Although the absence of Trm2 in isolation shows no physiological effect, its deletion has been demonstrated to induce lethality in four strains carrying mutations in tRNA^{Ser(CGA)23}, indicating that the stabilising nature of m⁵U54 may only be observed when the structure of a tRNA is affected in another

manner. Intriguingly, although three of the four mutants require catalytically active Trm2, and therefore m⁵U54, to be present for stability, one mutation described is entirely rescued through the expression of a catalytically inactive Trm2. It is therefore suggested that in addition to introducing the stabilising role of m⁵U54, Trm2 itself may possess a chaperone-like function that is separate from its catalytic role. A separate endo-exonuclease activity has been claimed for Trm2, which is preserved following deletion of the C-terminal methyltransferase domain²⁴. Through this activity, Trm2 is proposed to contribute to the repair of double-strand breaks by the 5'-3' resection of DNA ends. However, how this additional activity would explain the phenotypes observed with tRNA^{Ser(CGA)} mutants is unclear.

Efforts to characterise the modification profile of human tRNAs have identified the presence of m⁵U54 in the majority of cytoplasmic tRNAs as well as a small number of mitochondrial tRNAs. A very recent study demonstrated that human TRMT2A is responsible for introduction of the majority of m⁵U in human RNA, and that it targets U54 of cytosolic tRNAs²⁵However, the enzyme responsible for m⁵U in human mt-tRNA remains to be characterised. Likewise, the methyltransferase responsible for the introduction of m⁵U429 in mammalian mitochondrial 12S rRNA is yet to be identified. In this work, we aim to identify the ortholog of Trm2 operating in human mitochondria and to study the consequences of its loss.

Results

TRMT2B is a putative methyltransferase localised to human mitochondria

The m⁵U54 modification has been identified in both cytoplasmic and mitochondrial tRNAs in humans²⁶, with the former recently identified to be catalysed by TRMT2A²⁵, one of the two human orthologs of yeast Trm2 along with TRMT2B. As a mitochondrial role for TRMT2A was not ruled out by Carter et al.25, we set out to identify which of these paralogs may be operating within human mitochondria. An alignment of protein sequences from a range of species shows that the SAM binding site is highly conserved in the TRMT2A and TRMT2B paralogs. Whilst this is also the case for the remainder of the active site in TRMT2A, TRMT2B displays some dramatic divergences in some species (Figure 1). The proposed common mechanism for SAM-dependent m⁵U methyltransferases, supported by the crystal structure of TrmA¹⁸, entirely depends on the involvement of a nucleophilic cysteine and a proton extracting glutamate (Figure S1). Whilst these two residues are conserved in all species analysed for TRMT2A, a number of species contain mutations altering the catalytic cysteine in TRMT2B, which would be predicted to very severely impede the enzymes methyltransferase activity. The majority of these species belong to a single subfamily, the Bovinae, in which this otherwise well conserved cysteine is substituted for tyrosine (Figure 1). The finding that the bovine TRMT2B homolog appears catalytically inactive is in agreement with the initially surprising observation that m⁵U54, one of the most common tRNA modifications, is absent from all bovine mt-tRNAs²⁷. However, m⁵U54 is highly abundant in bovine cyto-tRNAs²⁶, it is tempting to speculate therefore, that these cytosolic substrates are methylated by the functional TRMT2A, which does not operate on mt-tRNAs.

The observation that bovine cyto-tRNAs are methylated at U54, whilst mt-tRNAs are not, could be explained by the solely cytosolic localisation of a catalytically active TRMT2A, and the mitochondrial localisation of a catalytically inactive TRMT2B. To test this hypothesis, the sequences of both paralogs were analysed for the likelihood of an N-terminal mitochondrial targeting sequence (MTS). In all three of the programs used to predict mitochondrial localisation (MitoProt II²⁸, Target P 1.1²⁹, and Predotar³⁰), the TRMT2A sequence returned very low scores across all species analysed, consistent

with a non-mitochondrial role. These scores were significantly higher for TRMT2B, indicating possible mitochondrial targeting (**Figure 1**). To confirm the mitochondrial localization of human TRMT2B, HeLa cells were transiently transfected with a C-terminal GFP-tagged TRMT2B and localised based on fluorescence. Through this analysis, TRMT2b was found to colocalise with the known mitochondrial protein TOM20 (**Figure 2**). Taken together these results show TRMT2B is a mitochondrial localised protein.

TRMT2B is a mitochondrial m⁵U54 tRNA methyltransferase

Next, we set out to determine mtRNA targets for TRMT2B. Due to the location of position 5 on the Hoogsteen, rather than Watson-Crick edge (Figure S2A), its methylation to form m⁵U does not interfere with the processivity of a reverse transcriptase, and therefore cannot be detected by primer extension without prior treatment. The presence of m⁵U can be inferred, however, due to its resistance to depyrimidination in the presence of hydrazine, a process which unmodified uracil is susceptible to (Figure S2A). Subsequent treatment with aniline results in phosphodiester bond cleavage at abasic sites, which are then detected due to the accumulation of primers that are unable to extend further (Figure S2B). In order to test the predicted role of TRMT2B, the aforementioned technique was used to test the U54 methylation status following transfection with siRNAs targeted to deplete TRMT2B. For mt-tRNA^{Pro}, which has been previously identified as containing m⁵U54³¹, the degree of stalling at U54, relative to downstream U49, is notably increased following TRMT2B siRNA transfection compared to an untransfected control (Figure **3A**). To confirm the role of TRMT2B in m⁵U54 methylation the same assay was repeated using RNA extracted from a TRMT2B knock-out HAP1 cell line. Correspondingly, the degree of stalling at U54 was found to be drastically increased in the knock out cell line relative to a control, consistent with the absence of m⁵U54 (**Figure 3B**). In agreement with the previously identified role for TRMT2A²⁵, the m⁵U54 status of cytosolic tRNAs were found to be unaffected following the loss of TRMT2B activity (Figure S3). Collectively, these results show TRMT2B is a mitochondrial protein responsible for the modification of position 54 in mt-tRNAs.

TRMT2B is a mitochondrial m⁵U429 12S rRNA methyltransferase

An m⁵U methylation has also been previously identified at U426 within the small 12S rRNA from hamster mitochondria¹¹. A sequence alignment of this region shows a very high degree of conservation across a range of eukaryotic species (Figure 4A). This sequence conservation is also present in the small 16S rRNA from E.coli where it forms the 790-loop, and whilst the corresponding uracil (U788) is not methylated, mutations within this loop yielded no fully formed 30S subunit³². The corresponding human residue, U429, is located within the central domain of 12S rRNA in helix 27 (Figure 4B), the loop of which is in very close proximity to the codon-anticodon site between bound mRNA and tRNA (Figure 4C). As this loop displays similarity to the consensus T-loop, and m⁵U has been detected at this position in hamster mitochondria, 12S U429 may also act as a substrate for TRMT2B, in addition to mttRNAs. To test whether TRMT2B is responsible for modification of 12S U429 in human mitochondria, the presence or absence of m⁵U was tested following an RNA treatment of hydrazine and aniline in wild type and TRMT2B knockout cells. Very little stalling at U429 was observed in wild type cells (Figure 4D), consistent with a modification conferring resistance to hydrazine. On the contrary, stalling at U429 is significantly increased in RNA extracted from TRMT2B knockout cells(Figure 4D). These results are consistent with human 12S containing an m⁵U methylation, as has been shown for hamster, and with this methylation being catalysed by TRMT2B.

Mitochondrial tRNA stability and aminoacylation are unaffected by the loss of TRMT2B

Incorrect folding as a consequence of hypomodification has been shown to disrupt the interaction between a tRNA and its cognate aminoacyl-tRNA synthetase^{33,34}. In order to assess the impact of m⁵U54 loss on tRNA charging, RNA extracted from WT and TRMT2B KO cells was subjected to acidic-PAGE, allowing for charged and uncharged tRNAs to be distinguished by their differing electrophoretic mobilities. In this analysis, the degree of aminoacylation for three m⁵U54-containing mt-tRNAsshows no change as a result of the loss of TRMT2B (**Figure 5A**). Interestingly, the migration pattern of mt-tRNA^{LeuUUR} is altered between the wild-type and knockout cell lines, but this shift is

present in both the acylated and deacylated samples, and therefore independent of aminoacylation. The conditions in which acidic-PAGE gels are run may allow for the preservation of certain tRNA secondary structures³⁵, and therefore this electrophoretic shift is likely an indication of the structural contribution made by m⁵U54.

As in vitro studies have pointed towards a role for m⁵U54 in tRNA thermal stability³⁶, the loss of TRMT2B has the potential to induce a temperature-sensitive phenotype. Whilst the stability of mature tRNAs is typically unaffected by heat-stress, a 6 hour heat-shock at 43 °C induces a 60 % reduction in the levels of initiator cyto-tRNA^{Met}, which coincidentally is one of the few cytoplasmic tRNAs to lack m⁵U54³⁷. The steady state levels of mt-tRNAs were assessed through northern blotting following RNA extraction from wild-type and knockout cells which were incubated at 43 °C for between 2 and 12 hours, or kept at 37 °C (0 hrs). No decrease in the steady state levels was observed for m⁵U54-bearing or m⁵U54-absent tRNAs, either in the wildtype or the knock-out cells (Figure 5B). Whilst this suggests no decrease in the stability of m⁵U54-lacking tRNAs, a constant steady state level could be maintained by a mtDNA transcription rate sufficiently high to replenish any degraded tRNA. Therefore, in order to test if this is the case, cells were treated with ethidium bromide to block mitochondrial transcription^{38,39}. RNA was extracted from wild-type and TRMT2B knockout cells at a range of time points between 6 and 36 hours, following the addition of 250 µg/mL of ethidium bromide, along with untreated cells (0 hrs). The rate of degradation for m⁵U54-bearing or m⁵U54-absent tRNAs showed no variation between the wild-type and knockout cell line (Figure 5C). Therefore, these data suggest no difference in the stability of mt-tRNAs following the loss of m⁵U54.

Mitoribosomestability is not disrupted by the loss of TRMT2B

The disruption of assembly pathways through the loss of an rRNA modification has been previously shown to result in the degradation of subunits that are unable to be incorporated into monosomes⁴⁰. In order to determine if TRMT2B activity contributes towards mitoribosome biogenesis, the steady state levels of protein components of the mitochondrial small 28S subunit were, therefore, assessed by western blotting. However, of the three MRPS proteins determined, the loss of m⁵U429 appears to have no discernible effect on their steady state levels (**Figure 6A**). Likewise, the loss of

m⁵U429 also has no effect on the steady-state levels of 12S mt-rRNA itself relative to 16S mt-rRNA (**Figure 6B**). As for mt-tRNAs, the effect of m⁵U429 on 12S thermal stability was determined by a 43 °C heat shock for between 2 and 12 hours. Interestingly, 12S mt-rRNA displayed a significantly greater susceptibility to heat-induced degradation compared to 16S rRNA, however, no difference in the rate of degradation was observed between the wild-type and knockout cell lines (**Figure 6C**). An analysis of 12S stability in the absence of replenishment from mitochondrial transcription also identifies no difference in the stability of 12S mt-rRNA resulting from the loss of TRMT2B (**Figure 6D**).

The loss of TRMT2B has no significant impact on mitochondrial translation

Although the loss either m⁵U54 or m⁵U429 have caused no detectable differences in the stability of mt-tRNAs or 12S mt-rRNA, their absence may instead be detrimental to the efficiency or fidelity of mitochondrial translation. To this end, the steady state levels of representative subunits from respiratory chain complexes were assessed through western blotting, however this displayed no significant difference resulting from the loss of TRMT2B (Figure 7A). Similarly, the rate of mitochondrial protein synthesis was measured by the incorporation of [35S] labelled methionine into nascent polypeptides. Once again, no difference between the wildtype and knockout cell line was observed (Figure 7B). Potentially, differences in the mitochondrial translation rate that are too subtle to distinguish through the assays described above, would be expected to provide cells with a growth advantage that would become apparent over a significantly long period of expansion. Wildtype and TRMT2B knockout cells were plated at a low confluency and the cell density measured over a 140 hour time course of growth. These growth curves were performed in either a high glucose medium or low glucose medium, with the latter exacerbating any growth disadvantage stemming from mitochondrial dysfunction, as cells are forced to rely more greatly on oxidative phosphorylation than glycolysis. Of note, growth in medium containing galactose as the sole carbon source, resulted in considerable cell death in both the wildtype and TRMT2B knockout HAP1 cell lines, obscuring accurate measurements. Under both conditions tested, the TRMT2B knockout cell line exhibited no statistically significant decrease in growth rate compared with the wildtype control (Figure 7C).

Discussion

TRMT2B catalyses the formation of m⁵U54 and m⁵U429 in mt-tRNAs and 12S rRNA, respectively.

In *S.cerevisiae*, the methyltransferase Trm2 is dual localised, catalysing the formation of m⁵U54 in both cyto-tRNAs and mt-tRNAs²¹, however a homology search of the human genome identified two potential orthologs, TRMT2A and TRMT2B. On the basis of mitochondrial localisation and the loss of m⁵U54 in mt-tRNAs in TRMT2Bablated cells, this work concludes that TRMT2B is responsible for the m⁵U54methyltransferase activity in human mitochondria. By extension, this work corroborates an earlier finding that TRMT2A is responsible for this activity in the cytosol²⁵. In addition, the presence of m⁵U429 in 12S mt-rRNA, predicted from its detection in hamster mitochondria, is supported by this study, and also appears to be a product of TRMT2B. This makes TRMT2B the second human mitochondrial methyltransferase found to operate on both mt-tRNAs and mt-rRNA, following the revelation that the mt-tRNAm¹A58-methyltransferase TRMT61B also introduces the same modification at position 947 in 16S mt-rRNA⁴¹. The existence of m⁵U modifications in both tRNAs and rRNAs is also well known within Archaea and Bacteria, however here they are performed by separate enzymes. For example, *E.coli* expresses three m⁵U-methyltransferase paralogs, TrmA catalysing m⁵U54 in tRNAs, RImC catalysing m⁵U747 in 23S rRNA, and RImD catalysing m⁵U1939 in 23S rRNA⁴².

How does TRMT2B methylation contribute to mitochondrial translation?

The near-ubiquity in bacterial and eukaryotictRNA sequences²⁶,decreased tRNA stability *in vitro*³⁶, and a fundamental role in tRNA structure suggested by the convergent evolution of sterically similar m¹Ψ54⁴³, would lead one to the conclusion that m⁵U54 holds a pivotal role in translation, with severe consequences resulting from its loss. In reality, the precise biological role for this modified nucleotide has proven difficult to determine since its identification more than 50 years ago⁴⁴. The present

study identifies the enzyme responsible for this modification in human mitochondria as TRMT2B, and also shows that the same enzyme additionally catalyses the formation of m⁵U429 in 12S mt-rRNA. Furthermore, functional studies of TRMT2B appear to show the same apparent lack of phenotype identified following the deletion of yeast Trm2, with no defect observed in mt-RNA stability, mitochondrial translation, or cell growth following the loss of TRMT2B. The perceived lack of phenotype in both yeast and human cells is likely the result of either the effect being too subtle and so below the detection limits of the experiments performed, or the effect is context specific, and the environmental conditions required for the effect to become evident have not yet been applied. An effect such as this is observed for the human cyto-tRNA modifiers NSUN2 and METTL1, where phenotypes are only observed when both enzymes are depleted in conjunction³⁷. A degree of functional redundancy may be a common feature of tRNA 'core modifications', with the absence of two or more, or their loss together with primary sequence changes, required to induce defects in translation. It is also likely that phenotypes are not being observed simply because the growth conditions are not challenged in the right manner, therefore external environmental changes such as the presence of ribosome inhibitors will also be required to differentiate between the wild type and knockout cell line.

The absence of a catalytically active TRMT2B in both bovine and rat mitochondria also raises doubts surrounding the importance of m⁵U54 in mitochondrial tRNAs relative to their cytosolic counterparts. Mitochondrial tRNAs are well known for their sometimes dramatic divergences from well conserved features found in 'canonical tRNAs' present in bacteria or eukaryotic cytosol⁴⁵. An altered reliance on otherwise well conserved tRNA modifications is likely to also be a product of these significant shifts in the RNA primary sequences. The high degree of sequence conservation evident in the remainder of bovine and rat TRMT2B is not indicative of a product of gene decay. Instead, it appears likely that bovine TRMT2B retains its RNA binding properties, perhaps now acting solely as a tRNA chaperone. If further work is able to uncover a phenotype resulting from the loss of TRMT2B, it will be important to determine the extent to which it can be rescued by a catalytic mutant, in order to unravel the relative contributions made by m⁵U54 and tRNA binding.

To date, 10 modified bases have been identified in the rRNA of mammalian mitochondria; with this work establishing TRMT2B as responsible for m⁵U429, the enzymes responsible are now known for all of the modified sites determined thus far. With regard to the other modified sites found alongside m⁵U429 in the 12S rRNA, the loss of the modification has been clearly demonstrated to have a detrimental effect on mitochondrial translation. In the recent identification of METTL15 as responsible for the catalysis of m⁴C839, the loss of the enzyme was shown to impair mitoribosome assembly with a concomitant reduction in mitochondrial protein synthesis (Van Haute et al., in press). Likewise, loss of either NSUN4 catalysing m⁵C841⁴⁶ and TFB1M catalysing m₂⁶A936 and m₂⁶A937⁴⁷, have also been shown to impact mitoribosome assembly. Similar effects have also been observed for modifications made to the 16S rRNA. Depletion of MRM2 and MRM3, responsible for the 2'-O-ribose methylations Um1369 and Gm1370, respectively, results in a corresponding disruption to the assembly of the large mitoribosome subunit⁴⁸. Likewise, diminished Ψ1397 resulting from RPUSD4 depletion has been shown to reduce the steady state levels of 16S rRNA, induce aberrant assembly of the mitoribosome large subunit, and severely reduce the rate of mitochondrial translation⁴⁹. Future work, perhaps focusing on specific cell types, developmental stages, or environmental conditions, will be required to uncover the contribution of TRMT2B to mitochondrial translation.

Materials and Methods

Cell Maintenance

All cell lines were maintained in humidified incubators at 5 % CO₂ and 37 °C, unless otherwise stated. Cells were cultured in Dulbecco's Modified Eagle Medium (DMEM), containing 4.5 g/L glucose, 110 mg/L sodium pyruvate, supplemented with 10 % foetal bovine serum (FBS), 100 U/ml penicillin and 100 μg/ml streptomycin. Wild-type and TRMT2B Knockout (Product ID: HZGHC004364c004) HAP1 cell lines were purchased from Horizon Discovery.

siRNA-mediated protein depletion

Stealth siRNAs (HSS129214, HSS129216, and HSS188304) were obtained from Thermo Fisher Scientific and transfected into HeLa cells using Lipofectamine RNAiMAX Reagent (Thermo Fisher Scientific).

Subcellular Localisation by Confocal Microscopy

The full-length TRMT2B cDNA construct (Source Bioscience, CatNo: IRATp970B1220D) was cloned into a pmaxGFP vector. HeLa cells were grown on coverslips and transiently transfected with the TRMT2B-GFP construct using Lipofectamine 2000 (ThermoFisher Scientific) and after 24 hours cells were visualised by confocal microscopy, with cells treated with DAPI for nuclear staining and mitochondria immuno-stained for TOM20 as described previously⁵⁰.

Detection of 5-methyluridine by primer extension

RNA was extracted from cells at 60 - 80 % confluency using TRIzol reagent (ThermoFisher Scientific), following the manufacturer's instructions. The Aniline-Hydrazine cleavage of total RNA was performed in a two-step procedure: the incubation of RNA with hydrazine which modifies uridines and its derivatives, followed by the cleavage of hydrazine-modified RNA at uridines by aniline. The resulting

14

cleavage is then detected via primer extension (Figure S2). To begin, 5 µg of pelleted

RNA was resuspended in 20 µL of chilled 50 % hydrazine hydrate and incubated on

ice for 5 minutes. The reaction was then stopped with the addition of a 1/10th volume

of 3 M NaOAc at pH 5.2 and 3 volumes of 100 % ethanol. The sample was then

precipitated at -80 °C for>12 hours. Following this, the precipitated hydrazine-treated

sample was centrifuged and the pellet resuspended in 1 M aniline-acetate pH 4.5. The

sample was incubated at 60 °C for 20 minutes, and the RNA then precipitated again

and resuspended in 30 µL of water.

The reverse transcription primer extension reactions were performed as in (48), with

the following primers used:

mt Pro m5U54: TGGTCAGAGAAAAGTC

mt 12S m5U429: GGGCTAAGCATAGTGGGGTATC

cyto-Asp m5U54: TGGCTCCCCGTCGGGGAATC

cyto-Glu_m5U54: TGGTTCCCTGACCGGGAAT

Northern Blotting

RNA was extracted from cells at 60 - 80 % confluency using TRIzol reagent

(ThermoFisher Scientific) and subjected to northern blotting as described

previously^{51,52}. Briefly, total RNA was resolved on 1% agarose gels containing 0.7 M

formaldehyde in 1× MOPS buffer (mt-rRNAs) or on 10% UREA-PAGE in 1× GTB

buffer (mt-tRNAs), or on 6.5% UREA-PAGE in 100mM NaOAc pH 5.0 (aminoacyl-mt-

tRNAs), transferred to a nylon membrane, ultraviolet-crosslinked to the membrane and

hybridized with radioactively labelled T7-transcribed radioactive RNA-probes.

Western Blotting

20-30 µg of total extracted protein was diluted to an equal volume and a ⅓ volume of

NuPAGE LDS 4 x sample buffer and loaded on SDS-PAGE 4-12% bis-tris gels (Life

Technologies) and transferred onto a membrane using iBlot 2 Dry Blotting System

(Thermo Fisher Scientific). The following antibodies were used: rabbit anti-MRPS17

(Proteintech 18881-1-AP, 1:1000), rabbit anti-MRPS18b (Proteintech 16139-1-AP,

15

1:1000), rabbit anti-MRPS35 (Proteintech 16457-1-AP, 1:1000), Total OXPHOS Human WB antibody cocktail (Abcam, ab110411, 1:1000), goat anti-rabbit IgG HRP (Promega W4011, 1:2000), goat, anti-mouse IgG HRP (Promega W4021).

[35S]-methionine metabolic labeling of mitochondrial proteins

The labelling of newly synthesised mtDNA-encoded proteins was performed as in Rorbach *et al.*⁴⁸. Briefly, exponentially growing cells were incubated in methionine/cysteine-free medium for 10 min before the medium was replaced with methionine/cysteine-free medium containing 10% dialysed FCS and emetine dihydrochloride (100 μ g/mL) to inhibit cytosolic translation. Following a 20 min incubation, 120 μ Ci/mL of [35 S]-methionine (Perkin Elmer) was added and the cells were incubated for 30 min. Cells were washed with PBS, lysed, and 30 μ g of protein was loaded on 10-20% Tris-Glycine SDS-PAGE gels. Dried gels were visualized and quantified with a Phosphorlmager system with ImageQuant software.

Disclosure statement

No potential conflict of interest was reported by the authors.

Supplementary material

Supplementary data for this article can be accessed [link]

References

- 1. Rebelo-Guiomar P, Powell CA, Van Haute L, Minczuk M. The mammalian mitochondrial epitranscriptome. *Biochim Biophys Acta Gene Regul Mech.* 2019;1862(3):429-446.
- 2. Van Haute L, Dietmann S, Kremer L, et al. Deficient methylation and formylation of mt-tRNAMet wobble cytosine in a patient carrying mutations in NSUN3. *Nat Commun*. 2016;7:12039.
- 3. Garone C, D'Souza AR, Dallabona C, et al. Defective mitochondrial rRNA methyltransferase MRM2 causes MELAS-like clinical syndrome. *Hum Mol Genet*. 2017;26(21):4257-4266.
- 4. Powell CA, Nicholls TJ, Minczuk M. Nuclear-encoded factors involved in post-transcriptional processing and modification of mitochondrial tRNAs in human disease. *Front Genet*. 2015;6:79.
- 5. Boczonadi V, Ricci G, Horvath R. Mitochondrial DNA transcription and translation: clinical syndromes. *Essays Biochem.* 2018;62(3):321-340.
- 6. Bessho Y, Shibata R, Sekine S -i., et al. Structural basis for functional mimicry of long-variable-arm tRNA by transfer-messenger RNA. *Proc Natl Acad Sci.* 2007;104(20):8293-8298.
- Kazantsev A V., Krivenko AA, Harrington DJ, Holbrook SR, Adams PD, Pace NR. Crystal structure of a bacterial ribonuclease P RNA. *Proc Natl Acad Sci.* 2005;102(38):13392-13397.
- 8. Toor N, Keating KS, Taylor SD, Pyle AM. Crystal Structure of a Self-Spliced Group II Intron. *Science (80-).* 2008;320(5872):77-82.
- 9. Serganov A, Huang L, Patel DJ. Coenzyme recognition and gene regulation by a flavin mononucleotide riboswitch. *Nature*. 2009;458(7235):233-237.
- 10. Chan CW, Chetnani B, Mondragón A. Structure and function of the T-loop structural motif in noncoding RNAs. *Wiley Interdiscip Rev RNA*. 2013;4(5):507-522.
- 11. Dubin DT. Methylated nucleotide content of mitochondrial ribosomal RNA from hamster cells. *J Mol Biol.* 1974;84(2):257-273.
- 12. Baer RJ, Dubin DT. Methylated regions of hamster mitochondrial ribosomal RNA: structural and functional correlates. *Nucleic Acids Res.* 1981;9(2):323-337.
- Hamdane D, Skouloubris S, Myllykallio H, Golinelli-Pimpaneau B. Expression and purification of untagged and histidine-tagged folate-dependent tRNA:m5U54 methyltransferase from Bacillus subtilis. *Protein Expr Purif.* 2010;73(1):83-89.
- 14. Lartigue C, Lebaudy A, Blanchard A, et al. The flavoprotein Mcap0476 (RlmFO) catalyzes m5U1939 modification in Mycoplasma capricolum 23S rRNA. *Nucleic Acids Res*.

- 2014;42(12):8073-8082.
- Madsen CT, Mengel-Jørgensen J, Kirpekar F, Douthwaite S. Identifying the methyltransferases for m(5)U747 and m(5)U1939 in 23S rRNA using MALDI mass spectrometry. *Nucleic Acids Res.* 2003;31(16):4738-4746.
- 16. Ranaei-Siadat E, Fabret C, Seijo B, Dardel F, Grosjean H, Nonin-Lecomte S. RNA-methyltransferase TrmA is a dual-specific enzyme responsible for C5-methylation of uridine in both tmRNA and tRNA. *RNA Biol.* 2013;10(4):572-578.
- 17. Gu X, Ofengand J, Santi D V. In vitro methylation of Escherichia coli 16S rRNA by tRNA (m5U54)-methyltransferase. *Biochemistry*. 1994;33(8):2255-2261.
- Alian A, Lee TT, Griner SL, Stroud RM, Finer-Moore J. Structure of a TrmA-RNA complex: A consensus RNA fold contributes to substrate selectivity and catalysis in m5U methyltransferases. *Proc Natl Acad Sci U S A*. 2008;105(19):6876-6881.
- Bjork GR, Neidhardt FC. Physiological and Biochemical Studies on the Function of 5-Methyluridine in the Transfer Ribonucleic Acid of Escherichia coli. J Bacteriol. 1975 Oct;124(1):99-111.
- Persson BC, Gustafsson C, Bergt DE, Bjork GR. The gene for a tRNA modifying enzyme, m5U54-methyltransferase, is essential for viability in Escherichia coli. *Biochemistry*. 1992;89:3995-3998.
- 21. Hopper AK, Furukawa AH, Pham HD, Martin NC. Defects in modification of cytoplasmic and mitochondrial transfer RNAs are caused by single nuclear mutations. *Cell.* 1982;28(3):543-550.
- 22. Nordlund ME, Johansson JO, von Pawel-Rammingen U, Byström AS. Identification of the TRM2 gene encoding the tRNA(m5U54)methyltransferase of Saccharomyces cerevisiae. *RNA*. 2000;6(6):844-860.
- 23. Johansson MJO, Byström AS. Dual function of the tRNA(m(5)U54)methyltransferase in tRNA maturation. *RNA*. 2002;8(3):324-335.
- Choudhury SA, Asefa B, Webb A, Ramotar D, Chow TY-K. Functional and genetic analysis of the Saccharomyces cerevisiae RNC1/TRM2: evidences for its involvement in DNA doublestrand break repair. *Mol Cell Biochem*. 2007;300(1-2):215-226.
- 25. Carter J-M, Emmett W, Mozos IR, et al. FICC-Seq: a method for enzyme-specified profiling of methyl-5-uridine in cellular RNA. *Nucleic Acids Res.* July 2019.
- 26. Machnicka MA, Milanowska K, Osman Oglou O, et al. MODOMICS: a database of RNA modification pathways--2013 update. *Nucleic Acids Res.* 2013;41(D1):D262-D267.

- 27. Suzuki T, Suzuki T. A complete landscape of post-transcriptional modifications in mammalian mitochondrial tRNAs. *Nucleic Acids Res.* 2014;42(11):7346-7357.
- 28. Claros MG, Vincens P. Computational method to predict mitochondrially imported proteins and their targeting sequences. *Eur J Biochem.* 1996;241(3):779-786.
- 29. Emanuelsson O, Nielsen H, Brunak S, von Heijne G. Predicting Subcellular Localization of Proteins Based on their N-terminal Amino Acid Sequence. *J Mol Biol.* 2000;300(4):1005-1016.
- 30. Small I, Peeters N, Legeai F, Lurin C. Predotar: A tool for rapidly screening proteomes for N-terminal targeting sequences. *Proteomics*. 2004;4(6):1581-1590.
- 31. Brulé H, Holmes WM, Keith G, Giegé R, Florentz C. Effect of a mutation in the anticodon of human mitochondrial tRNA Pro on its post-transcriptional modification pattern. *Nucleic Acids Res.* 1998;26(2):537-543.
- 32. Desai PM, Culver GM, Rife JP. Site-directed mutants of 16S rRNA reveal important RNA domains for KsgA function and 30S subunit assembly. *Biochemistry*. 2011;50(5):854-863.
- 33. Degoul F, Brulé H, Cepanec C, et al. Isoleucylation properties of native human mitochondrial tRNAlle and tRNAlle transcripts. Implications for cardiomyopathy-related point mutations (4269, 4317) in the tRNAlle gene. *Hum Mol Genet*. 1998;7(3):347-354.
- 34. Helm M, Giegé R, Florentz C. A Watson-Crick Base-Pair-Disrupting Methyl Group (m1A9) Is Sufficient for Cloverleaf Folding of Human Mitochondrial tRNA Lys. *Biochemistry*. 1999;38(40):13338-13346.
- 35. Hegg LA, Thurlow DL. Residual tRNA secondary structure in "denaturing" 8M urea/TBE polyacrylamide gels: effects on electrophoretic mobility and dependency on prior chemical modification of the tRNA. *Nucleic Acids Res.* 1990;18(10):2993-3000.
- 36. Davanloo+ P, Sprinzl+ M, Watanabet K, Albani M, Kersten H. Role of ribothymidine in the thermal stability of transfer RNA as monitored by proton magnetic resonance. *Nucleic Acids Res.* 1979;6(4April).
- 37. Okamoto M, Fujiwara M, Hori M, et al. tRNA Modifying Enzymes, NSUN2 and METTL1, Determine Sensitivity to 5-Fluorouracil in HeLa Cells. 2014.
- 38. Knight E. Mitochondria-associated ribonucleic acid of the HeLa cell. Effect of ethidium bromide on the synthesis of ribosomal and 4S ribonucleic acid. *Biochemistry*. 1969;8(12):5089-5093.
- 39. Yasukawa T, Hino N, Suzuki T, Watanabe K, Ueda T, Ohta S. A pathogenic point mutation reduces stability of mitochondrial mutant tRNA(IIe). *Nucleic Acids Res.* 2000;28(19):3779-3784.
- 40. Metodiev MD, Lesko N, Park CB, et al. Methylation of 12S rRNA Is Necessary for In Vivo

- Stability of the Small Subunit of the Mammalian Mitochondrial Ribosome. *Cell Metab.* 2009;9(4):386-397.
- 41. Bar-Yaacov D, Frumkin I, Yashiro Y, et al. Mitochondrial 16S rRNA Is Methylated by tRNA Methyltransferase TRMT61B in All Vertebrates. *PLoS Biol.* 2016;14(9):e1002557.
- 42. Auxilien S, Rasmussen A, Rose S, et al. Specificity shifts in the rRNA and tRNA nucleotide targets of archaeal and bacterial m5U methyltransferases. *RNA*. 2011;17(1):45-53.
- 43. Pang H, Ihara M, Kuchino Y, et al. Structure of a modified nucleoside in archaebacterial tRNA which replaces ribosylthymine. 1-Methylpseudouridine. *J Biol Chem.* 1982;257(7):3589-3592.
- 44. Zamir A, Holley RW, Marquisee M. Evidence for the occurence of a common pentanucleotide sequence in the structures of transfer ribonucleic acids. *J Biol Chem.* 1965;240:1267-1273.
- 45. Salinas-Giegé T, Giegé P. tRNA Biology in Mitochondria. *Int J Mol Sci.* 2015;16(3):4518-4559.
- 46. Metodiev MD, Spåhr H, Loguercio Polosa P, et al. NSUN4 Is a Dual Function Mitochondrial Protein Required for Both Methylation of 12S rRNA and Coordination of Mitoribosomal Assembly. Barsh GS, ed. *PLoS Genet*. 2014;10(2):e1004110.
- 47. Seidel-Rogol BL, McCulloch V, Shadel GS. Human mitochondrial transcription factor B1 methylates ribosomal RNA at a conserved stem-loop. *Nat Genet*. 2003;33(1):23-24.
- 48. Rorbach J, Boesch P, Gammage PA, et al. MRM2 and MRM3 are involved in biogenesis of the large subunit of the mitochondrial ribosome. *Mol Biol Cell*. 2014;25(17):2542-2555.
- 49. Zaganelli S, Rebelo-Guiomar P, Maundrell K, et al. The pseudouridine synthase RPUSD4 is an essential component of mitochondrial RNA granules. *J Biol Chem.* 2017;292(11):4519-4532.
- Minczuk M, Kolasinska-Zwierz P, Murphy MP, Papworth MA. Construction and testing of engineered zinc-finger proteins for sequence-specific modification of mtDNA. *Nat Protoc*. 2010;5(2):342-356.
- 51. Rorbach J, Gao F, Powell CA, et al. Human mitochondrial ribosomes can switch their structural RNA composition. *Proc Natl Acad Sci.* 2016;113(43):12198-12201.
- 52. Pearce SF, Rorbach J, Van Haute L, et al. Maturation of selected human mitochondrial tRNAs requires deadenylation. *Elife*. 2017;6.

Additional information

Funding

Medical Research Council, UK (MC_UU_00015/4) is gratefully acknowledged for support of our work.

Acknowledgements

We would like to thank the members of the Mitochondrial Genetics Group at the MRC-MBU for stimulating discussions during the course of this work. Maciej Szukszto is acknowledged for his technical assistance in the experiments presented in Figure 2.

Authors' contribution

C.A.P. conceived, designed and performed the experiments, undertook the data analysis and wrote the manuscript; M.M. oversaw the project and wrote the manuscript. Both authors commented and approved the final version of the manuscript.

Figure Legends

Figure 1 I Sequence Analysis of m⁵U54-methyltransferase homologs. Schematic of

protein domains in both TRMT2A and TRMT2B. Homologous sequences identified through

BLAST searches aligned for key catalytic regions, with the degree of shadowing representing

the extent of conservation for a given residue. Nucleophilic cysteine shown in red, Proton

extracting glutamate shown in blue. Species that contain only a single predicted m⁵U54-

methyltransferase indicated in blue text. Species that contain a TRMT2B sequence that is

predicted to be catalytically inactive are indicated in red text. These two paralogs were

analysed for the presence of an N-terminal mitochondrial localisation signal (MTS) using

computational prediction tools. Higher scores (between 0 and 1) indicate a higher probability

of mitochondrial localisation, which are also colour coded. NA, not applicable; ND, no data

Figure 2 I TRMT2B is localised to mitochondria. TRMT2B-GFP cDNA construct transfected

into HeLa cells and detected by fluorescence (top right, green). Nuclei were stained using

DAPI (top left, blue). The mitochondrial network was stained using antibodies against the

known mitochondrial protein TOM20 (bottom left, red). Colocalisation of TRMT2B and TOM20

appears as yellow in a digitally overlaid image (bottom right).

Figure 3 I TRMT2B catalyses m⁵U54 in mt-tRNA^{Pro}. (a) Schematic of mt-tRNAPro T-loop

showing annealed primer to be extended (red line) and the position of m⁵U54 (blue text). HeLa

cell derived RNA, either following a 6-day siRNA mediated depletion of TRMT2B or untreated,

was subsequently either untreated (-) or treated with hydrazine for either 5 or 10 minutes,

followed by aniline, to specifically cleave at unmodified uridine residues. This RNA was

subjected to RT-PEx using a [32P]-end labelled primer complementary to the region upstream

of m⁵U54 (red line). The nucleotide sequence of the tRNA, corresponding to stalling events at

each position, is shown to the side of the panel. Quantification values represent the ratio

between stalling at U54 and stalling at the next uridine residue (U49), after the values in the

22

untreated lanes had been subtracted from both to account for background. (b) RT-PEx

reactions as performed above with RNA derived from a HAP1 parental cell line with wild-type

(WT) or a HAP1 TRMT2B knockout cell line (KO). Error bars = SEM, n = 3.

Figure 4 I TRMT2B catalyses m⁵U429 in 12S mitochondrial rRNA. (a) Alignment of the

small ribosomal RNA (rRNA) from a range of species in a region corresponding to helix 27 in

human 12Smt-rRNA. The degree of shadowing represents the extent of conservation for a

given residue, with U429 (or the corresponding position in other species) shown in blue

background. The T-loop consensus sequence is displayed above for comparison. (b)

Schematic of human 12S mt-rRNA, helix 27, and the location of m⁵U429 (blue circle). **(c)** The

structure of the human mitoribosome highlighting U429 (blue), the bound mRNA (green), and

the adjacently bound tRNA (red). (d) Separation and detection of RT-PEx products using a

[32P]-end labelled primer complementary to the region upstream of m⁵U429 in 12S rRNA.

Extension reactions performed on RNA derived from a HAP1 wild-type (WT) and a HAP1

TRMT2B knockout cell line (KO), with or without hydrazine-aniline treatment. The nucleotide

sequence of 12S rRNA is shown to the side of the panel. Quantification values represent the

ratio between stalling at U429 and stalling at the next uridine residue (U424). Error bars =

SEM, n = 4.

Figure 5 I tRNA aminoacylation and stability following the loss of TRMT2B. (a) High

resolution acidic polyacylamide gel electrophoresis (PAGE) northern blot analysis of total RNA

extracted from HAP1 wild-type (WT) or TRMT2B knockout cell line (KO). RNA was either

maintained in low pH conditions to preserve aminoacylation (Ac), or intentionally deacylated

prior to being run on the gel (dAc). The blots were probed with the mt-tRNA-specific riboprobes

as indicated, with the tRNAs known to contain m⁵U54 in red text. (b) High resolution PAGE

northern blot analysis of total RNA extracted from HAP1 parental cell line (WT), or a HAP1

TRMT2B knockout cell line (KO), following their growth at 43 °C for between 2 and 12 hours.

Control cells kept at 37 °C shown as '0 hrs'. The blots were probed with the mt-tRNA-specific

23

riboprobes as indicated, with the tRNAs known to contain m⁵U54 in red text. Quantification

values were plotted as a percentage of the untreated 0 hr RNA. (c) As above following

exposure to 250 µg/mL ethidium bromide (EtBr) for between 6 and 36 hours. Control cells

grown in media containing no EtBr shown as '0 hrs'. The blots were probed with the mt-tRNA-

specific riboprobes as indicated, with the tRNAs known to contain m5U54 in red text.

Quantification values were plotted as a percentage of the untreated 0 hr RNA, after they had

been normalised to 5S to control for RNA loading.

Figure 6 I Mitoribosome integrity following the loss of TRMT2B. (a) Western blot using

lysates derived from HAP1 WT and KO probed using antibodies against three protein

components on the small subunit. Coomassie gel staining shown as loading

control. **(b)** Northern blot analysis of total RNA extracted from HAP1 parental cell line (WT),

or a HAP1 TRMT2B knockout cell line (KO). (c) Northern blot analysis of total RNA extracted

from HAP1 WT and TRMT2B KO cell lines following their growth at 43 °C for between 2 and

12 hours. Quantification values plotted as the ratio between 12S and 16S. (d) Northern blot

analysis of total RNA extracted from HAP1 WT and TRMT2B KO cell lines following their

exposure to 250 µg/mL ethidium bromide (EtBr) for between 2 and 12 hours.

Figure 7 I Mitochondrial translation following the loss of TRMT2B. (a) Western blot

analysis of steady-state levels of OXPHOS subunits in HAP1 parental cell line (WT), and the

HAP1 TRMT2B knockout cell line (KO). (b) Assessment of de novo mitochondrial protein

synthesis through [35S]-methionine incorporation in the HAP1 WT and KO cell lines.

Coomassie gel staining was used as a control for protein loading. (c) Growth curves obtained

by Incucyte kinetic imaging system of HAP1 WT and KO cell lines. Cells were grown for 140

24

hours in the presence of 'high' (4.5 g/L) or 'low' (1 g/L) glucose.

Figure 1




Figure 2








Figure 3









SUPPLEMENTAL FIGURES

Figure S1: The catalytic mechanism of m⁵U-methyltransferases, showing the involvement of the nucleophilic cysteine, the proton extracting glutamate, and S-adenosylmethionine (SAM).




Figure S2: Detection of 5-methyluridine in RNA (a) The hydrazinolysis of uracil in RNA is mediated through the nucleophilic attack of C6 by hydrazine, and the subsequent reaction with C4, forming a pyrazole which is spontaneously cleaved from the glycosidic nitrogen. The resulting abasic site is susceptible to β-elimination at both the 3' and 5' phosphates in the presence of aniline. A methyl group at C5 protects the pyrimidine ring from nucleophilic attack, and therefore subsequent strand cleavage at this position **(b)** Primer extension (red arrow) following Hydrazine-Aniline treatment will result in stalled extension products corresponding to unmodified uracils in the original sequence, whereas primers will read through m⁵U. These products are then separated through gel electrophoresis.




Figure S3: m⁵U54 in cyto-tRNAs is retained in TRMT2B KO cells. Separation and detection of RT-PEx products using a [³²P]-end labelled primer complementary to the region upstream of m⁵U54 (red line) in cyto-tRNAAsp and cyto-tRNAGlu. Extension reactions performed on RNA derived from a HAP1 wild-type (WT) TRMT2B knockout cell line (KO), and following hydrazine-aniline treatment (WT+H/A and KO + H/A). Quantification values represent the ratio between stalling at U54 and stalling at the next uridine residue (U35), after the values in the untreated lanes had been subtracted from both to account for background. The nucleotide sequence of the tRNA, corresponding to stalling events at each position, is shown to the side of the panel, with the addition of the modifications present for cyto-tRNA^{Glu} where the modification profile is known.